Despite the low response rates and immune-related adverse events in some cancer patients, both CTLA4 and PD-1/PD-L1 inhibitors have broadly demonstrated their value to boost potent and durable anti-tumor responses and to increase the average life expectancy for metastatic cancer patients [23]. This evidence concerns the gene PDCD1 and neoplasm.